The study will evaluate the efficacy, safety and tolerability of prucalopride over 12 weeks of treatment in subjects aged 18 years and older with chronic non-cancer pain, suffering from opioid induced constipation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
174
placebo
1 or 2 mg prucalopride once daily before breakfast
Unnamed facility
Leuven, Belgium
Percent of Subjects With an Average Frequency of >=3 Spontaneous Bowel Movements Per Week
A bowel movement (BM) was defined as spontaneous if no laxatives were taken in the 24 hours preceding that BM.
Time frame: 12 weeks
Plasma Concentration of Prucalopride at Week 2
Time frame: Week 2
Plasma Concentration of Prucalopride at Week 8
Time frame: Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.